Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-AnalysisEmma Grigor, Manoj M. Lalu, Brian Hutton et al.|Transfusion Medicine Reviews|2019Cited by 190
Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trialsMadison Foster, Manoj M. Lalu, Dean Fergusson et al.|Research Involvement and Engagement|2020Cited by 49
Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview studyJustin Presseau, Gisell Castillo, Manoj M. Lalu et al.|Trials|2021Cited by 25
Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trialGisell Castillo, Justin Presseau, Manoj M. Lalu et al.|BMJ Open|2021Cited by 23
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-AnalysisManoj M. Lalu, Dean Fergusson, Samuel Igweokpala et al.|Transfusion Medicine Reviews|2025Cited by 4